International Myeloma Society Opens Applications for More Than $3 Million in 2027 Research Funding
Applications now open for awards supporting translational research and early-career scientists working to improve treatment and advance cures for multiple myeloma.
Boston, MA (October 15, 2026) — The International Myeloma Society (IMS), in partnership with the Paula and Rodger Riney Foundation, is accepting applications for more than $3 million in research funding through its 2027 Translational Research and Career Development awards. The awards support research to improve the prevention, early detection, diagnosis and treatment of multiple myeloma and related plasma cell disorders, while developing the next generation of researchers in the field.
“Multiple myeloma research has led to some of the most significant advances in cancer treatment. Just this year, IMS and the International Myeloma Working Group announced a consensus definition of cure, reflecting what is possible through sustained research and global collaboration,” said Philippe Moreau, MD, President of the International Myeloma Society. “Through our partnership with the Paula and Rodger Riney Foundation, we are investing in the ideas and researchers who will build on that progress for generations to come.”
Since 2021, IMS has awarded more than $18.5 million to 105 research projects across 66 institutions in 25 countries. The 2027 cycle offers two funding opportunities:
IMS Translational Research Award
Grants of $175,000 to $250,000 support investigator-initiated research with the potential to improve the prevention, early detection, diagnosis and treatment of plasma cell disorders, with a focus on advancing a cure for multiple myeloma. Proposals may explore new tests, imaging technologies, treatments or other approaches with clear potential for clinical application.
IMS Career Development Award
Grants of up to $75,000 support emerging scientists pursuing research careers in plasma cell disorders and encourage collaboration across institutions. Applicants must hold an MD or PhD, or be completing a PhD focused on plasma cell disorders. Funding may include salary support and travel expenses.
Applications for both awards are due January 29, 2027, at 11:59 p.m. EST. Full eligibility requirements, application guidelines and submission forms are available through the IMS Grant Portal. https://www.myelomasociety.org/grants/
About the International Myeloma Society (IMS)
The International Myeloma Society is the only global non-profit focused on myeloma research and clinical care. Representing thousands of experts across more than 75 countries, IMS accelerates cures, fosters collaboration, and transforms patient care. The organization emphasizes funding research (with $18.5 Million Provided) and advancing clinical care access in low-to-middle income countries. https://www.myelomasociety.org/
Media Contact:
Taylor Hallabuk; thallabuk@denterlein.com
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
